HomepageSUNPHARMA • NSE
add
Sun Pharmaceutical Industries Ltd
Vorige slotkoers
₹ 1.669,60
Dag-range
₹ 1.650,40 - ₹ 1.678,90
Jaar-range
₹ 1.495,25 - ₹ 1.960,35
Beurswaarde
4,00 bln. INR
Gem. volume
2,63 mln.
Koers/winst
35,32
Dividendrendement
0,96%
Primaire beurs
NSE
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (INR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 129,59 mld. | 8,14% |
Bedrijfskosten | 75,61 mld. | 20,16% |
Netto inkomsten | 21,50 mld. | -19,01% |
Netto winstmarge | 16,59 | -25,10% |
Winst per aandeel | 10,01 | -13,02% |
EBITDA | 34,05 mld. | 9,13% |
Effectief belastingtarief | 33,68% | — |
Balans
Totale activa
Totale passiva
| (INR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 249,88 mld. | 30,89% |
Totale activa | 921,01 mld. | 7,77% |
Totale passiva | 196,15 mld. | 6,85% |
Totaal aandelenvermogen | 724,86 mld. | — |
Uitstaande aandelen | 2,39 mld. | — |
Koers-boekwaardeverhouding | 5,52 | — |
Rendement op activa | — | — |
Rendement op kapitaal | 9,40% | — |
Kasstroom
Nettomutatie in liquide middelen
| (INR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 21,50 mld. | -19,01% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Opgericht
1983
Hoofdvestiging
Website
Werknemers
43.000
